Ceftobiprole Medocaril Sodium: An Overview

Drug Overview

Ceftobiprole Medocaril Sodium is a fifth-generation cephalosporin antibiotic primarily used to treat severe bacterial infections, such as Staphylococcus aureus bloodstream infections. It is administered intravenously and is known for its broad-spectrum activity, being effective against a variety of bacteria, including gram-positive organisms like Staphylococcus aureus, including Methicillin-resistant strains (MRSA), and some gram-negative pathogens like Escherichia coli and Pseudomonas aeruginosa. The FDA (U.S. Food and Drug Administration) approved it as an intravenous solution in 2024.

For Patients:

What Are the Clinical Indications for Ceftobiprole Medocaril Sodium?

Ceftobiprole treats severe infections involving deeper soft tissue or significant tissue damage, such as abscesses, ulcers, or infections following surgery. It is particularly effective against Staphylococcus aureus (including methicillin-resistant strains), streptococci, and other gram-positive and gram-negative bacteria that commonly cause these infections.

What Is the Dosage of Ceftobiprole Medocaril Sodium?

• It is given at 500 milligrams (mg) every eight hours as an intravenous (IV) infusion over two hours.

• It is given for seven to 14 days or longer, based on the severity of the infection and clinical guidelines.

What Are the Things to Inform the Doctor Before Taking the Drug?

The patient must inform the doctor if they are on other medications before starting this drug.

They should also inform them about the below-mentioned conditions:

• Pregnancy.

• Heart disease.

• Liver disease.

• Kidney diseases.

• Cancer.

• Breastfeeding.

How Is Ceftobiprole Medocaril Sodium Administered?

• Ceftobiprole Medocaril Sodium is administered via intravenous (IV) infusion.

• The drug comes as a powder, reconstituted with sterile water for injection, and then diluted with an IV solution, like normal saline (0.9 percent sodium chloride) or five percent dextrose.

• The infusion is typically given over 120 minutes (two hours).

• The standard dosage is 500 mg every eight hours, but this can vary based on the specific infection being treated and patient-specific factors like renal function.

• Administration is typically in a hospital or clinical setting, where healthcare professionals can manage the infusion and monitor for any adverse effects or complications.

What Are the Side Effects of Ceftobiprole Medocaril Sodium?

• Nausea.

• Headache.

• Injection site reactions (pain, swelling, redness).

Missed Dose:

• Doubling the next dose to compensate for a missed dose is not recommended. This can increase the risk of adverse effects without providing additional therapeutic benefits.

• Inform the healthcare team as soon as possible about the missed dose. They can provide specific guidance on how to manage it and whether it requires rescheduling or other adjustments.

Overdose:

There is no specific information on the clinical signs and symptoms of an overdose of Ceftobiprole medocaril sodium. If a patient receives a dose higher than the recommended regimen and experiences unexpected adverse reactions related to Ceftobiprole Medocaril Sodium, discontinue the medication, provide symptomatic treatment, and implement general supportive care.

Storage:

• Ceftobiprole Medocaril Sodium vials are stored in the refrigerator at temperatures between two degrees Celsius and eight degrees Celsius, shielded from light.

• Store them in their original carton until they are ready for use.

For Doctors:

Indication:

Ceftobiprole medocaril sodium is indicated for the treatment of Staphylococcus aureus bloodstream infection (bacteremia) in adult patients, including those with right-sided infective endocarditis, caused by both methicillin-susceptible and methicillin-resistant strains.

Dose:

• Administer each prepared intravenous infusion solution of Ceftobiprole Medocaril Sodium to adult patients over a two-hour period at a concentration of 2.67 milligrams per milliliter ( mg/mL).

• The duration of treatment for Staphylococcus aureus bloodstream infection in adults can be up to 42 days.

Dosing Considerations:

• The standard dosage for adults is 500 mg, typically given every eight hours.

• Ceftobiprole is administered intravenously (IV), and each infusion takes about two hours.

• The recommended concentration for the prepared solution is 2.67 mg/mL.

• For Staphylococcus aureus bloodstream infection, treatment duration can range from seven to 14 days but may extend up to 42 days, depending on the severity of the infection and clinical judgment.

• Patients with renal (kidney) impairment may require dosage adjustments based on their creatinine clearance (CrCl) levels.

• Special considerations may be necessary for elderly patients, those with pre-existing conditions, or those on other medications.

• Regular monitoring for therapeutic effectiveness and potential adverse effects is crucial, with adjustments made as needed.

• Dosing consistency is important for antibiotic effectiveness; missed doses should be addressed promptly with healthcare guidance.

What Are the Pharmacological Aspects of Ceftobiprole Medocaril Sodium?

Mechanism of Action:

Ceftobiprole medocaril sodium, a fifth-generation cephalosporin antibiotic, inhibits bacterial cell wall synthesis, a critical process for bacterial survival. It achieves this by targeting and binding to penicillin-binding proteins (PBPs). PBPs are enzymes involved in the final stages of synthesizing peptidoglycan, an essential component of bacterial cell walls that provide structural integrity and shape.

Ceftobiprole exhibits a high affinity for a broad range of PBPs, focusing on PBP2a, a variant commonly found in methicillin-resistant Staphylococcus aureus (MRSA). PBP2a differs from other PBPs in its reduced binding affinity for beta-lactam antibiotics, which grants MRSA its resistance to these drugs. However, ceftobiprole's unique structure allows it to bind to PBP2a, overcoming this resistance mechanism.

Upon binding to PBPs, Ceftobiprole inhibits the cross-linking of peptidoglycan chains, a crucial step in cell wall synthesis. Without this cross-linking, the bacterial cell wall weakens, leading to cell lysis and ultimately, bacterial death. This action forms the basis of ceftobiprole's bactericidal activity.

The broad-spectrum nature of Ceftobiprole results from its ability to bind to multiple types of PBPs found in various Gram-positive and Gram-negative bacteria. This broad-spectrum activity makes Ceftobiprole effective against a diverse range of bacteria, including methicillin-resistant and methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis, Enterococcus faecium, and various Gram-negative organisms such as Escherichia coli and Pseudomonas aeruginosa.

Pharmacokinetics:

• Absorption: Ceftobiprole Medocaril Sodium is exclusively administered via intravenous (IV) infusion, ensuring direct entry into the bloodstream. This method guarantees complete absorption, bypassing the gastrointestinal system and avoiding issues related to oral bioavailability. Intravenous administration allows for rapid achievement of therapeutic drug levels, providing an immediate response to bacterial infections.

• Distribution: Upon entering the bloodstream, Ceftobiprole spreads widely across the body, reaching various tissues and fluids. This extensive distribution is beneficial in treating systemic infections, where broad tissue penetration is necessary for effective therapy. Ceftobiprole achieves therapeutic concentrations in critical areas like the skin, lungs, and bloodstream, which is why it is indicated for conditions such as complicated skin and soft tissue infections, community-acquired pneumonia, and bloodstream infections.

• Metabolism: Ceftobiprole Medocaril Sodium is a prodrug, meaning it requires conversion into its active form to exhibit its pharmacological effects. The conversion process occurs through esterase enzymes in the bloodstream and other tissues. This conversion from prodrug to active Ceftobiprole is rapid, typically occurring within minutes of administration, allowing the active drug to target and disrupt bacterial cell wall synthesis quickly.

• Excretion: The primary route of excretion for Ceftobiprole is through the kidneys. Approximately 80 percent of the drug is excreted unchanged in the urine, indicating that the kidneys play a significant role in its clearance. The remainder is metabolized into inactive compounds and excreted through other pathways. Given this high rate of renal excretion, it is crucial to assess kidney function when determining the dosage and frequency of administration. Patients with impaired renal function may require dose adjustments to avoid drug accumulation and potential toxicity. Monitoring creatinine clearance (CrCl) is often used to guide these adjustments.

• Half-Life: Ceftobiprole's half-life is relatively short, typically around three to four hours in adults with normal renal function. This short half-life implies that the drug is rapidly cleared from the body, which impacts dosing frequency. To maintain therapeutic levels, Ceftobiprole is often dosed every eight hours. In cases of renal impairment, the half-life may be extended, necessitating dose adjustments to prevent drug accumulation.

Pharmacodynamics:

• The drug's efficacy depends on time-dependent killing, meaning its effectiveness is associated with maintaining a therapeutic concentration in the bloodstream over a certain period.

• Ceftobiprole's binding to PBP2a helps overcome certain resistance mechanisms in MRSA. However, as with all antibiotics, the development of resistance remains a risk, necessitating judicious use and adherence to clinical guidelines.

Clinical Studies and Efficacy:

• Ceftobiprole Medocaril Sodium is a fifth-generation cephalosporin used to treat Staphylococcus aureus bloodstream infections (SAB), including right-sided infective endocarditis.

• A randomized, controlled, double-blind, multinational, multicenter trial evaluated its efficacy and safety for treating SAB in adults.

• In this trial, patients received Ceftobiprole Medocaril Sodium 667 mg (equivalent to 500 mg ceftobiprole) IV every six hours from day one to day eight, then 667 mg IV every eight hours from day nine onwards.

• Patients eligible for the study had at least one positive blood culture for Staphylococcus aureus within 72 hours before randomization and signs and symptoms of bacteremia.

• Complications included acute bacterial skin and skin structure infections, intra-abdominal abscesses, osteoarticular infections, chronic dialysis, and definite right-sided infective endocarditis.

• Overall success at the post-treatment evaluation (PTE) visit, 70 days after randomization, was defined by survival, symptom improvement, bacteremia clearance, no new complications, and no use of other antibacterial drugs.

• Success rates at the PTE visit in the modified intent-to-treat (mITT) population were 69.8 percent for Ceftobiprole Medocaril Sodium and 68.7 percent for the comparator.

• Microbiological eradication was achieved in 82 percent of patients treated with Ceftobiprole Medocaril Sodium and 77 percent in the comparator group.

• All-cause mortality between randomization and the PTE visit was 9.0 percent for Ceftobiprole and 9.1 percent for the comparator.

• S. aureus bloodstream clearance, defined as two consecutive days with negative blood cultures, was achieved after a median of four days for both treatment groups.

• S. aureus clearance in patients with methicillin-susceptible S. aureus (MSSA) took a median of three days for Ceftobiprole and four days for the comparator. For methicillin-resistant S. aureus (MRSA), both groups achieved clearance in a median of five days.

• Relapse of Staphylococcus aureus bacteremia occurred in one percent of patients treated with Ceftobiprole Medocaril Sodium and two percent in the comparator group.

What Are the Contraindications of Ceftobiprole Medocaril Sodium?

Ceftobiprole Medocaril Sodium is contraindicated in patients with a history of severe hypersensitivity to Ceftobiprole Medocaril Sodium or other cephalosporins.

Warnings and Precautions:

• Increased Mortality with Unapproved Use in Ventilator-Associated Bacterial Pneumonia Patients: In a clinical trial, there was a higher mortality rate among patients with ventilator-associated bacterial pneumonia (VABP) treated with Ceftobiprole Medocaril Sodium, with 35 out of 103 patients (34 percent) succumbing, compared to 24 out of 102 (24 percent) in the comparator group. The cause of this increased mortality is unknown, but most deaths were related to complications from infection or pre-existing comorbidities. Ceftobiprole medocaril sodium is not approved for treating VABP, as its safety and efficacy in this context have not been established.

• Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, have been observed in patients treated with Ceftobiprole medocaril sodium during clinical trials. Additionally, severe skin reactions and sometimes fatal hypersensitivity events have been reported with beta-lactam antibiotics. Before starting treatment with ceftobiprole, it is crucial to ask patients about prior hypersensitivity reactions to cephalosporins, penicillins, or other beta-lactam antibiotics. Cross-sensitivity among beta-lactams is well-documented, necessitating careful monitoring. If a hypersensitivity reaction occurs, discontinue Ceftobiprole and initiate appropriate treatment.

• Seizures and Other Central Nervous System Reactions: Seizures and other adverse central nervous system (CNS) reactions have been reported with Ceftobiprole Medocaril Sodium and other cephalosporins. These CNS reactions can range from nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, and neuromuscular excitability, to myoclonia, especially in patients with a history of epilepsy or when recommended dosages are exceeded due to renal impairment. Dosages for Ceftobiprole should be adjusted based on creatinine clearance. If CNS reactions, including seizures, occur, patients should undergo a neurological evaluation to determine whether to continue treatment with ceftobiprole.

• Clostridioides Difficile-Associated Diarrhea: Clostridioides difficile-associated diarrhea (CDAD) has been reported with almost all systemic antibacterial agents, including Ceftobiprole medocaril sodium. It can vary in severity from mild diarrhea to fatal colitis. Antibiotics disrupt the normal flora in the colon, allowing C. difficile to overgrow and produce toxins that cause CDAD. Hypertoxin-producing strains can lead to more severe outcomes and might require surgical intervention. If CDAD is suspected or confirmed, ongoing antibiotic therapy not directed at C. difficile should be stopped if possible. Management involves fluid and electrolyte balance, protein supplementation, and appropriate antibacterial treatment of C. difficile.

• Development of Drug-Resistant Bacteria: Ceftobiprole Medocaril Sodium should not be prescribed without a confirmed or strongly suspected bacterial infection or an appropriate prophylactic indication. This practice can develop drug-resistant bacteria, reducing the antibiotic's effectiveness and complicating future treatment options.

Specific Considerations

• Pregnancy: There is no specific data on the use of Ceftobiprole medocaril sodium in pregnant women to evaluate the potential risks of major birth defects, miscarriage, or other adverse outcomes for the mother or fetus. However, observational studies and case reports on the use of cephalosporins in pregnant women over the years have not demonstrated any drug-associated risks for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. These studies, however, have limitations such as small sample sizes, retrospective data collection, and inconsistent comparator groups, which means that the absence of risk cannot be conclusively established.

• Lactation: There is no information on the presence of Ceftobiprole in human breast milk, nor is it affected by breastfed infants or milk production. Studies on lactating rats indicate Ceftobiprole is excreted into their milk at low concentrations. Given this, Ceftobiprole could also be present in human milk. When considering breastfeeding, the benefits for the infant should be weighed against the clinical need for Ceftobiprole and any potential adverse effects on the child due to the drug or underlying maternal conditions.

• Pediatric Use: The safety and effectiveness of Ceftobiprole medocaril sodium for treating community-acquired bacterial pneumonia (CABP) in pediatric patients aged three months to under 18 years have been established. This indication is supported by data from trials with adults, along with additional pharmacokinetic, safety, and efficacy data from pediatric trials. However, its safety and effectiveness for treating CABP in pediatric patients under three months of age and for treating acute bacterial skin and skin structure infections (ABSSSI) or Staphylococcus aureus bloodstream infections (SAB) in pediatric patients, have yet to be established.

• Geriatric Use: Among 835 adult patients treated with Ceftobiprole Medocaril Sodium in trials, people were 65 or older, including 85 who were 75 or older. There were no significant differences in safety or effectiveness between patients aged 65 and older and younger adults. Additionally, no clinically significant changes in pharmacokinetics were observed in older patients compared to younger adults. Dosage adjustments for geriatric patients should be based on renal function, as trials and clinical pharmacology studies indicate.